Illumina, Inc. $ILMN Shares Bought by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 81.0% during the second quarter, Holdings Channel reports. The firm owned 334,791 shares of the life sciences company’s stock after purchasing an additional 149,801 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Illumina were worth $31,942,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in ILMN. LPL Financial LLC increased its stake in Illumina by 10.5% during the 1st quarter. LPL Financial LLC now owns 91,606 shares of the life sciences company’s stock worth $7,268,000 after buying an additional 8,739 shares during the period. Bank of Nova Scotia boosted its position in Illumina by 16.6% in the 1st quarter. Bank of Nova Scotia now owns 3,525 shares of the life sciences company’s stock valued at $280,000 after buying an additional 501 shares during the period. Vanguard Group Inc. grew its stake in shares of Illumina by 3.5% in the first quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company’s stock worth $1,298,928,000 after acquiring an additional 558,243 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Illumina by 5.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 721,047 shares of the life sciences company’s stock worth $57,208,000 after acquiring an additional 37,502 shares in the last quarter. Finally, Chicago Partners Investment Group LLC increased its position in shares of Illumina by 81.5% during the first quarter. Chicago Partners Investment Group LLC now owns 2,802 shares of the life sciences company’s stock worth $214,000 after acquiring an additional 1,258 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Buying and Selling at Illumina

In related news, Director Scott Gottlieb bought 500 shares of the stock in a transaction dated Monday, November 3rd. The stock was acquired at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the acquisition, the director owned 12,523 shares in the company, valued at approximately $1,529,433.99. This represents a 4.16% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.60% of the company’s stock.

Illumina Trading Up 0.7%

ILMN opened at $128.96 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. Illumina, Inc. has a one year low of $68.70 and a one year high of $153.06. The company has a market cap of $19.71 billion, a P/E ratio of 28.91, a PEG ratio of 2.31 and a beta of 1.44. The business’s 50-day simple moving average is $111.21 and its 200-day simple moving average is $100.92.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The firm’s quarterly revenue was up .4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on ILMN shares. JPMorgan Chase & Co. lifted their target price on Illumina from $100.00 to $105.00 and gave the company a “neutral” rating in a report on Friday, October 31st. Robert W. Baird set a $109.00 price target on Illumina in a report on Friday, October 31st. Daiwa America cut Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 12th. TD Cowen raised their target price on shares of Illumina from $110.00 to $115.00 and gave the company a “hold” rating in a report on Friday, October 31st. Finally, Canaccord Genuity Group lifted their price target on shares of Illumina from $105.00 to $112.00 and gave the stock a “hold” rating in a research note on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Illumina has an average rating of “Hold” and a consensus target price of $115.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.